
FDA Approves Viloxazine Extended-Release Capsules for ADHD
Viloxazine extended-release capsules are indicated as a once-daily, flexible-dose nonstimulant drug for attention-deficit hyperactivity disorder.
The FDA has approved viloxazine extended-release capsules (Qelbree; Supernus Pharmaceuticals) for the treatment of
Viloxazine has now been approved for the treatment of ADHD in children 6 years of age and up, adolescents, and adults. Viloxazine extended-release capsules are the first novel, nonstimulant option approved for adults with ADHD in 2 decades, according to Supernus.
“[The] approval marks a major advancement in the treatment of ADHD and is an important milestone just 1 year after the approval of Qelbree to treat pediatric patients. We are proud to bring a new novel nonstimulant option for adults into the market after two decades,” said Jack Khattar, president and CEO of Supernus Pharmaceuticals, in a press release.
Approximately 16 million individuals have ADHD in the United States. Although many children outgrow the condition, up to 90% of individuals with ADHD in childhood continue to manage the condition in adulthood, according to Supernus Pharmaceuticals.
A randomized, double-blind, placebo-controlled phase 3 trial showed that patients treated with viloxazineachieved the primary endpoint of a statistically significantly reduced change from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score compared with placebo (P = .004). The data also showed a significant improvement in AISRS subscale scores for inattention and hyperactivity/impulsivity symptoms among treated patients.
Further, adult patients administered viloxazine achieved the key secondary efficacy endpoint of change in Clinical Global Impression—Severity of Illness (CGI-S) scale from baseline to week 6 (P = .0023).
“Until today, nonstimulant ADHD options for adults have been very limited,” said Greg Mattingly, MD, founding partner of St. Charles Psychiatric Associates in St. Louis, in a press release. “This approval is positive news and offers a new novel option for the millions of American adults who are trying to find the right treatment to manage their ADHD symptoms."
Reference
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults. Supernus Pharmaceuticals. News release. April 29, 2022.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.